bDMARD treament strategy
Most patients with axial spondyloarthritis and arthritis psoriactica are initially treated the same, i.e. a TNF-inhibitor. However, we aim to investigate which drug should be prescribed as second line drug after discontinuation of the first TNF-inhibitor: another TNFi or something with a different mode of action.
Data has been collected from patients with axial spondyloarthritis and arthritis psoriactica who have visited the outpatient clinic between 2012-2022. According to the guidelines, up to 2019, patients received another TNF inhibitor after discontinuation of the first TNF-inhibitor (cycle group). The guidelines have been changed, and since 2019 patients receive an IL-17 inhibitor upon discontination of the first TNF inhibitor (swap group). These two groups will be compared to each other in order to investigate the efficacy of a cycle versus swap strategy.